FDA Approves Eli Lilly's Baqsimi, the first treatment for Severe Hypoglycemia
The U.S. FDA gave its approval to Baqsimi nasal powder, for the treatment of Severe Hypoglycaemia in patients with diabetes ages four and older. Baqsimi is a powder administered into the nose and is the first non-injectable emergency treatment for severe episodes of hypoglycaemia. The nasal powder comes with a single-use dispenser and works by stimulating the liver to increase the levels of stored glucose into the blood-stream. It is noteworthy that Eli Lilly’s Baqsimi can be administered to an unconscious person as it does not need to be inhaled. Severe Hypoglycaemia occurs when the bloo...
